Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib Phase II in Relapsing Multiple Sclerosis
NCT02975349Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of evobrutinib in relapsing-remitting multiple sclerosis (RRMS) (5 arms), sponsored by EMD Serono. Primary endpoint: Total Number of Gadolinium-Enhancing T1 Lesions. Started Mar 2017; status: terminated.
02
Drugs
evobrutinib
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02975349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975349.